The Claim
In adults with diabetes and no significant atherosclerosis, treatment with evolocumab reduces the risk of first major cardiovascular events, with similar hazard ratios observed in women (HR 0.71) and men (HR 0.67), indicating consistent benefit across sexes.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
For adults with diabetes who do not have advanced artery disease, the drug evolocumab lowers the chance of having a first heart attack, stroke, or other serious heart event, and this benefit is similar for both women and men.
See the scientific wording
In adults with diabetes and no significant atherosclerosis, evolocumab reduces the risk of first major cardiovascular events regardless of sex, with similar hazard ratios observed in both women (HR 0.71) and men (HR 0.67), indicating consistent benefit across genders.
A drug blocks a protein that normally removes cholesterol-cleaning receptors from the liver, so more receptors stay on the liver surface to pull cholesterol out of the blood. With less cholesterol in the blood, fatty deposits don't build up as much in artery walls, reducing the chance of blockages that cause heart attacks or strokes.
What the research says
1 studyThis study found that a cholesterol-lowering drug called evolocumab helped people with diabetes who hadn’t had a heart attack or stroke yet, by lowering their risk of future heart problems — and it worked well for both women and men, even though the exact numbers for each gender weren’t given.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.